首页> 外文OA文献 >Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy

【2h】

Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy

机译：III阶段Leap-011试验：一线Pembrolizumab与Lenvatinib患者患者，尿路上皮癌的患者有不合格接受基于铂的化疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Y. Loriot; A. Balar; R. de Wit; J.A. Garcia; P. Grivas; N. Matsubara; T.L. Frenkl; E. Sbar; X.C. Jia; T. Fouad; A.O. Siefker-Radtke;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pembrolizumab in Combination with Lenvatinib significantly improved progression-free Survival and Overall Survival compared to Chemotherapy in Phase III Study in Patients with advanced Endometrial Cancer after prior platinum-based Chemotherapy [J] . Breast care . 2021,第3期

机译：Pembrolizumab与Lenvatinib相结合的无与伦比的无进展生存和整体存活率与先前铂基化疗后先进子宫内膜癌患者的研究中的化疗相比
2. Long-term survival results of a randomized phase iii trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy [J] . BellmuntJ., FougerayR., RosenbergJ.E., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第6期

机译：铂类化学疗法失败后，晚期氟尿路上皮癌患者接受长春氟宁加联合最佳支持治疗与最佳支持治疗的随机III期试验的长期生存结果
3. PATIENT-REPORTED OUTCOME DATA FROM THE LUX-LUNG 8 PHASE III GLOBAL TRIAL OF AFATINIB VERSUS ERLOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY. [J] . Lee Karen, Goker Erdem, Coskun Hasan S., Oncology nursing forum . 2016,第2期

机译：LUX-LONG 8期III期全球临床试验报告的AFATINIB和ERLOTINIB对比继发于第一线铂类化疗的肺高级鳞状细胞癌的二线治疗。
4. CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma [C] . Zhien Feng, Lizhen Wang, Bingshun Wang, Academic Committee Conference of Shanghai key lab of stomatology . 2011

机译：CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm multicentre phase 2 trial [O] . Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, -1

机译：Atezolizumab作为不适合顺铂治疗的局部晚期和转移性尿路上皮癌患者的一线治疗：一项单臂多中心2期试验
7. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM) [O] . Karin Holmsten, Niels Viggo Jensen, Lene Sonne Mouritsen, 2020

机译：Vinflunine / gemcitabine与卡铂/吉西他滨，在顺铂型尿道癌患者中为一线治疗：随机期二期试验（Vingem）

Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅